Close

FDA Committee to Discuss Clovis Oncology's (CLVS) Rociletinib NDA on April 12th

February 12, 2016 8:59 AM EST Send to a Friend
Clovis Oncology, Inc. (NASDAQ: CLVS) announced that the U.S. Food and Drug Administration (FDA) has scheduled the New Drug Application ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login